多汗症治疗市场 - 按类型、治疗、年龄、最终用户、全球预测

在治疗选择的快速进步以及皮肤科和美容诊所的扩张的带动下，多汗症治疗市场规模预计从 2024 年到 2032 年将以 5.3% 的复合年增长率扩大。

最近，创新正在帮助开发更有效、更有针对性的疗法，例如新药物和微创手术，以覆盖更广泛的患者群体。此外，皮肤科和美容诊所也正在提高其能力和服务，为多汗症提供专门的治疗，以加强患者的取得和照护。例如，2024年6月，Botanix Pharmaceuticals宣布美国FDA已批准其12.45%的Sofdra（索匹罗铵）凝胶用于治疗腋下出汗过多，这标誌着多汗症治疗方案的重大进步。

整个市场分为类型、治疗、年龄、最终用户和地区。

根据治疗情况，预计从2024 年到2032 年，肉毒毒素注射领域的多汗症治疗市场价值将大幅增长，因为人们越来越多地采用肉毒毒素注射来更好地控制自己的症状并提高生活品质。这种方法包括将少量肉毒桿菌注射到受过度出汗影响的区域，例如腋下、手掌或脚部。此外，医疗保健提供者正在扩大这些注射剂的使用，为患者提供更个人化和针对性的治疗。

由于对多汗症提供专门治疗的需求不断增长，预计到 2032 年，皮肤科诊所最终用户领域的多汗症治疗行业将以复合年增长率大幅扩张。这些诊所正在采用先进的疗法，例如肉毒桿菌注射和新的局部疗法，以有效解决出汗过多的问题。皮肤科医生也致力于完善治疗方案并提供个人化护理计划，以更好地管理多汗症症状。

从地区来看，由于可支配收入的增加以及化妆品和美容行业的发展，欧洲多汗症治疗市场规模预计将在 2024 年至 2032 年间扩大。该地区的美容和美容行业正在整合新疗法和技术，以更有效地解决多汗症问题。此外，我们不断加强努力，增强治疗选择并扩大可用性。为欧洲各地寻求缓解出汗过多的个人提供更好的解决方案并提高整体治疗效果的持续改进将有利于行业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 多汗症盛行率增加
    • 意识和诊断率不断提高
    • 治疗技术的进步
  • 产业陷阱与挑战
    • 与治疗相关的副作用和风险
• 成长潜力分析
• 监管环境
• 技术景观
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 腋窝多汗症
• 手掌多汗症
• 足底多汗症
• 其他类型

第 6 章：市场估计与预测：按处理方式，2021 - 2032 年

• 主要趋势
• 局部治疗
• 口服药物
  • 抗胆碱药
  • 其他口服药物
• 肉毒毒素注射
• 离子电渗透疗法
• 手术治疗

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 50岁以下
• 50岁以上

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

• 主要趋势
• 医院
• 门诊手术中心
• 皮肤科诊所
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Avanor Healthcare Ltd.
• Brickell Biotech Inc.
• Dermadry Laboratories Inc.
• Dermavant Sciences Inc.
• Hugel, Inc.
• Eirion Therapeutics, Inc
• Eli Lilly and Company
• Intas Pharmaceuticals Ltd
• Kaken Pharmaceutical Co., Ltd.
• Maruho Co., Ltd.
• miraDry, Inc.
• SweatBlock

Hyperhidrosis Treatment Market size is projected to expand at 5.3% CAGR from 2024 to 2032, led by rapid advancements in treatment options along with the expansion of dermatology and aesthetic clinics.

Of late, innovations are helping in developing more effective and targeted therapies, such as new medications and minimally invasive procedures to reach a broader patient base. Moreover, dermatology and aesthetic clinics are also increasing their capacity and services to offer specialized treatments for hyperhidrosis for enhancing patient access and care. For instance, in June 2024, Botanix Pharmaceuticals announced that the U.S. FDA had approved its Sofdra (sofpironium) gel, 12.45%, for treating excessive underarm sweating, marking a significant advancement in hyperhidrosis treatment options.

The overall market is segregated into type, treatment, age, end-user, and region.

Based on treatment, the hyperhidrosis treatment market value from the botulinum toxin injections segment is estimated to rise at significant rate from 2024 to 2032 due to rising adoption for offering individuals more control over their symptoms and enhancing quality of life. This approach involves injecting small amounts of botulinum toxin into areas affected by excessive sweating, such as the underarms, palms, or feet. Moreover, healthcare providers are expanding the use of these injections to offer more personalized and targeted treatments for patients.

Hyperhidrosis treatment industry from the dermatology clinics end-user segment is anticipated to expand at substantial CAGR up to 2032, owing to the growing requirement to offer specialized treatments for hyperhidrosis. These clinics are incorporating advanced therapies, such as botulinum toxin injections and new topical treatments to address excessive sweating effectively. Dermatologists are also working on refining treatment protocols and providing personalized care plans to better manage hyperhidrosis symptoms.

Regionally, the Europe hyperhidrosis treatment market size is projected to expand between 2024 and 2032, on account of the rising disposable incomes and the growing cosmetic and aesthetic sector. The cosmetic and aesthetic sectors in the region are integrating new therapies and technologies to address hyperhidrosis more effectively. Additionally, increasing efforts are enhancing treatment options and expanding availability. The ongoing enhancements for offering better solutions and increasing the overall treatment efficacy for individuals seeking relief from excessive sweating across Europe will favor the industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hyperhidrosis
    • 3.2.1.2 Growing awareness and diagnosis rates
    • 3.2.1.3 Advancements in treatment technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and risk associated with treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Axillary hyperhidrosis
• 5.3 Palmar hyperhidrosis
• 5.4 Plantar hyperhidrosis
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Topical treatment
• 6.3 Oral medication
  • 6.3.1 Anticholinergics
  • 6.3.2 Other oral medications
• 6.4 Botulinum toxin injections
• 6.5 Iontophoresis
• 6.6 Surgical treatment

Chapter 7 Market Estimates and Forecast, By Age, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Below 50 years
• 7.3 Above 50 years

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory surgical centers
• 8.4 Dermatology clinics
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Avanor Healthcare Ltd.
• 10.3 Brickell Biotech Inc.
• 10.4 Dermadry Laboratories Inc.
• 10.5 Dermavant Sciences Inc.
• 10.6 Hugel, Inc.
• 10.7 Eirion Therapeutics, Inc
• 10.8 Eli Lilly and Company
• 10.9 Intas Pharmaceuticals Ltd
• 10.10 Kaken Pharmaceutical Co., Ltd.
• 10.11 Maruho Co., Ltd.
• 10.12 miraDry, Inc.
• 10.13 SweatBlock